N-Acetyl Semax Amidate

Neurotrophic Signaling

In murine models, Semax upregulates BDNF, NGF, and TrkB in a time- and dose-dependent manner. Effects extend beyond acute administration into sustained receptor-level changes relevant to synaptic consolidation.²

Transcriptomic Response to Ischemia

Genome-wide profiling in focal ischemia models shows Semax coordinates expression changes across immune response, vascular remodeling, and inflammatory signaling — suggesting neuroprotection through multiple pathways rather than one target.

Optic Neuropathy

Semax has been studied in glaucomatous optic neuropathy, where retinal ganglion cells (which are CNS neurons) showed protection. Patients receiving Semax demonstrated visual field preservation and improved contrast sensitivity — demonstrating that neuroprotective effects extend to retinal neurons.⁴

BDNF Biomarker Confirmation

A 2018 study of 110 post-stroke patients showed Semax elevated plasma BDNF regardless of rehabilitation timing. Higher BDNF correlated with faster functional recovery on standardized measures — bridging preclinical findings to human outcomes.¹

Acute Stroke

Meta-analysis of Russian trials indicates neurological deficits improve more rapidly over the first 10-14 days when Semax is added to standard care. Effects are most pronounced in moderate-to-severe presentations. Functional outcomes improved by day 21. A 2005 study of 30 patients with cerebrovascular insufficiency showed improved motor function restoration with intranasal Semax 12-18mg/day for 5-10 days.⁵

Three-Year Follow-Up

In 120 patients with chronic reduced cerebral blood flow, Semax produced 2.5x greater recovery at one year and 3x at three years. Controls plateaued at ~18 months; treated patients continued improving with repeated courses.

Clinical evidence comes primarily from Russian institutions. The stroke data, while substantial, has limited Western replication. Most studies track weeks to months rather than years.

The N-acetyl amidate modification enhances stability but creates a compound not identical to the Semax in trials — pharmacokinetic equivalence should not be assumed.

1. Polunin GS et al. "Semax and BDNF in post-stroke rehabilitation." Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PubMed
2. Eremin KO et al. "Semax regulates BDNF and TrkB expression in rat hippocampus." Brain Res. 2006. PubMed
3. Potaman VN et al. "Inhibition of enkephalin-degrading enzymes by Semax." Dokl Biochem Biophys. 2001. PubMed
4. Ioseliani OR et al. "Effects of Semax on visual function in glaucomatous optic neuropathy." Vestn Oftalmol. 2001. PubMed
5. Gusev EI et al. "Semax in prevention of disease progress in patients with cerebrovascular insufficiency." Zh Nevrol Psikhiatr Im S S Korsakova. 2005. PubMed
6. Sverdlov ED. "Semax, an analogue of ACTH(4-10), as potential agent for ADHD and Rett syndrome." Med Hypotheses. 2007. PubMed

For laboratory research use only.